Belite Bio to Present Phase 3 Stargardt Disease Trial Results at Key Retinal Conferences
Event summary
- Belite Bio will present topline results from the Phase 3 DRAGON study of tinlarebant for Stargardt’s disease at two major retinal conferences in July 2026.
- Presentations scheduled for ISCEV (July 8, Sydney) and ASRS (July 18, Montréal).
- Tinlarebant is an oral therapy targeting vitamin A-based toxins in degenerative retinal diseases.
The big picture
Belite Bio’s upcoming presentations mark a critical milestone in the development of tinlarebant, an oral therapy addressing a significant unmet need in Stargardt disease. The company’s strategic focus on degenerative retinal diseases positions it within a growing sector prioritizing novel treatments for inherited and age-related vision loss. Success in these trials could validate its pipeline and attract further investment or partnerships.
What we're watching
- Regulatory Pathway
- Whether tinlarebant’s Breakthrough Therapy and Orphan Drug designations will accelerate U.S. and international approval processes.
- Market Potential
- The pace at which Belite Bio can commercialize tinlarebant for Stargardt disease, given the lack of current approved treatments.
- Pipeline Expansion
- How Phase 3 DRAGON II and PHOENIX trial results will impact Belite Bio’s strategy in targeting geographic atrophy (GA) in dry AMD.